PLANTATION, Fla., Feb. 1 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex:
"VRA"; "VRA.U"; "VRA.WS") today announced that the Company is scheduled to
make a presentation at the BIO CEO & Investor Conference to be held in New
York City during February 12-14, 2007.
Event Details:
Meeting: Biotechnology Industry Organization (BIO) CEO & Investor
Conference
Presenter: Charles A. Rice, President & CEO, Viragen, Inc.
Date / Time: Tuesday, February 13th at 3:45 p.m.
Place: Waldorf-Astoria Hotel, New York City
The Company will conduct additional one-on-one meetings with
institutional investors, fund managers and investment bankers. To request
and schedule a meeting, please contact Douglas Calder, Director of
Communications, at (954) 233-8746 or at dcalder@viragen.com.
In other news, Viragen reported voting results from its 2006 Annual
Meeting of Stockholders held on January 25, 2007 in Plantation, Florida.
Stockholders approved all proxy voting items including:
- Reelection of Carl N. Singer and C. Richard Stafford as Class C members
of the Company's Board of Directors
- Viragen's 2006 Equity Compensation Plan
- Amendment to Viragen's Certificate of Incorporation to increase the
number of shares of common stock it is authorized to issue, from 250
million to 500 million
- Appointment of Ernst & Young LLP, as Viragen's independent registered
public accounting firm for the fiscal year ending June 30, 2007
About Viragen, Inc.:
With international operations in the U.S., Scotland and Sweden, we are
a bio-pharmaceutical company engaged in the research, development,
manufacture and commercialization of therapeutic proteins for the treatment
of cancers and viral diseases. Our product and product candidate portfolio
includes: Multiferon(R) (multi-subtype, human alpha interferon) which is
uniquely positioned in valuable niche indications, such as high-risk
malignant melanoma, other niche cancer indications and selected infectious
diseases; VG101, a humanized monoclonal antibody that binds selectively to
an antigen over-expressed on Stage IV malignant melanoma tumors; and VG102,
a highly novel humanized monoclonal antibody that binds selectively to an
antigen that is over-expressed on nearly all solid tumors. We are also
pioneering the development of the OVA(TM) System (Avian Transgenics), with
the renowned Roslin Institute, the creators of "Dolly the Sheep", as a
revolutionary manufacturing platform for the large-scale, efficient and
economical production of human therapeutic proteins and antibodies, by
expressing these products in the egg whites of transgenic hens.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements
that can be identified by such terminology such as "believes," "expects,"
"potential," "plans," "suggests," "may," "should," "could," "intends," or
similar expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results to be materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally;
the success of third- party marketing efforts; our ability to retain
third-party distributors; our ability to obtain or maintain patent and
other proprietary intellectual property protection; and competition in
general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements
to reflect circumstances or events that occur after the date the
forward-looking statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications of
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
